News Center

位置：

Honors Announcement

Group News

Media Reports

A Strong Start to the Year: Shijiazhuang Sihua Pharmaceutical Wins Three Prestigious Awards for High-Quality Development in the High-Tech Zone

Category:

Group News

发布时间：2026-03-09

【概要描述】 On February 28, the Shijiazhuang High-tech Industrial Development Zone held a conference on high-quality development, sounding the resounding call to sprint from the very start of the year. During the event, a list of enterprises that have made outstanding contributions to promoting the zone’s high-quality development was announced and commended, with Shijiazhuang Sihua Pharmaceutical honored with three prestigious awards: Industry Leader Enterprise, Innovation Demonstration Enterprise, and one of the Top Ten Taxpayers of the Year.

A Strong Start to the Year: Shijiazhuang Sihua Pharmaceutical Wins Three Prestigious Awards for High-Quality Development in the High-Tech Zone

On February 28, the Shijiazhuang High-tech Industrial Development Zone held a conference on high-quality development, sounding the resounding call to sprint from the very start of the year. During the event, a list of enterprises that have made outstanding contributions to promoting the zone’s high-quality development was announced and commended, with Shijiazhuang Sihua Pharmaceutical honored with three prestigious awards: Industry Leader Enterprise, Innovation Demonstration Enterprise, and one of the Top Ten Taxpayers of the Year.

In 2025, amid a severe and complex domestic and international economic environment, Shijiazhuang Sihua Pharmaceutical will remain firmly committed to the paramount task of high-quality development. With a focus on the unified national market and the dual circulation strategy—domestic and international—the company will deepen the implementation of its innovation-driven strategy, further promote the deep integration and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain, and accelerate the cultivation of new productive forces. The goal is to build an industrial ecosystem led by innovative pharmaceuticals, with specialty chemical drug formulations and active pharmaceutical ingredients as the core, and extended by high-end pharmaceutical packaging materials and distinctive bioproducts. Empowered by technological innovation and digital transformation, the company continues to rank among the industry leaders in the number of new product applications submitted and approved. To date, a total of 168 drug varieties comprising 220 dosage forms have either passed or been deemed to have passed the evaluation of generic drug quality and therapeutic equivalence. Leveraging an integrated “API-plus-formulation” development model, the company has delivered outstanding performance in national centralized procurement and renewal bids, as well as in inter-provincial alliance procurement, significantly enhancing product accessibility and market penetration. The “Shimen” brand has successfully established itself among China’s renowned consumer brands, achieving a new leap in both innovation influence and market competitiveness and laying a solid foundation for high-quality development.

“This weighty honor is both a full recognition of the company’s spirit of innovation, relentless progress, and pragmatic commitment to responsibility, as well as a heartfelt expectation and strong encouragement for the company to accelerate its transformation toward new, higher-quality development,” said a representative of Shijiazhuang No. 4 Pharmaceutical. “We will cherish this honor all the more, set even higher standards for ourselves, and press forward with a ‘start-at-full-throttle’ work ethic—tackling tough challenges head-on, forging ahead with courage and determination—to vigorously speed up our transition to innovative drugs and high-end generic medicines, ensure smooth domestic–international dual circulation, and strive to take the lead and set an example in promoting high-quality regional economic development and the high-quality growth of Shijiazhuang’s biopharmaceutical industry.”

Keywords:

Shijiazhuang Sihua Pharmaceutical has had 45 products across 55 specifications selected in the first through eighth rounds of national centralized procurement follow-up purchases.

Shijiazhuang Sihua Pharmaceutical Group’s Bosun Medical Devices Awarded by the Xinghua Municipal Party Committee and Municipal Government, Receiving Two Prestigious Honors: “Outstanding Taxpayer” and “Top Ten Enterprises in Technological Innovation”

Shijiazhuang Sihua Pharmaceutical has had 45 products across 55 specifications selected in the first through eighth rounds of national centralized procurement follow-up purchases.